Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients
Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S
Magnesium research · 0 citas
Etiquetas de revisión
Financiación no declaradaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2000-12-01 · Magnes Res · vol. 13 · número 4 · págs. 275–84
- Editorial
- National Institutes of Health
- Citado
- 5 citas · más que el 65% de estudios similares · 0.2× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Antiplatelet Therapy and Cardiovascular Diseases · Platelet Disorders and Treatments · Magnesium in Health and Disease
- Palabras clave
- magnesium oxide, aspirin, stable coronary artery disease, antithrombotic activity, platelet aggregation, P-selectin, adhesion molecules, ex vivo perfusion model, thrombosis
- MeSH
- monocytes, humans, coronary disease, thrombosis, electrolytes, magnesium, magnesium oxide, aspirin, lipids, thromboplastin, p-selectin, fibrinolytic agents, placebos, flow cytometry, administration, oral, prospective studies, cross-over studies, double-blind method, cell adhesion, platelet aggregation, aged, aged, 80 and over, middle aged, female, male, cholesterol, ldl, cholesterol, hdl, cholesterol, vldl
9 autores
- Michael Shechter🇺🇸Cedars-Sinai Medical Center; University of California, Los Angeles
- C. Noel Bairey Merz
- Maura J. Paul-Labrador
- Simcha Ron Meisel
- Robert K. Rude
- Mia D. Molloy
- J H Dwyer
- Paulesh K. Shah
- S Kaul
Resumen
El texto original del estudio, en el idioma en que se publicó.
The use of magnesium in the treatment of acute myocardial infarction remains controversial despite preliminary experimental evidence that magnesium plays a beneficial role as a regulator of thrombosis. The aim of our study was to determine whether oral magnesium treatment inhibits platelet-dependent thrombosis (PDT) in stable patients with coronary artery disease (CAD). In a randomized prospective, double-blind, cross-over and placebo controlled study, 42 patients with stable CAD (37 men, 5 women, mean age 68 +/- 9 years) on aspirin received either magnesium oxide tablets (800-1,200 mg/day) or placebo for 3 months (Phase 1) followed by a 4-week washout period, and the cross-over treatment for 3 months (Phase 2). PDT, platelet aggregation, platelet P-selectin flow-cytometry, monocyte tissue factor procoagulant activity (TF-PCA) and adhesion molecules density were assessed before and after each phase. PDT was evaluated by an ex-vivo perfusion model using the Badimon chamber. Median PDT was significantly reduced by 35 percent in patients who received magnesium versus placebo (D change from baseline: -24 vs. 26 microm2/mm; p = 0.02, respectively). There was no significant effect of magnesium treatment on platelet aggregation, P-selectin expression, monocyte TF-PCA or adhesion molecules. Oral magnesium treatment inhibits PDT in patients with stable CAD. This effect appears to be independent of platelet aggregation or P-selectin expression, and is evident despite aspirin therapy. These findings suggest a potential mechanism whereby magnesium may beneficially alter outcomes in patients with CAD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.